Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin Alfa Dose-Ranging in Active Systemic Lupus Erythematosus
jRCT2041210076Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of efavaleukin alfa in systemic lupus erythematosus (SLE) (4 arms), sponsored by Amgen. Primary endpoint: SRI-4 response at Week 52. Started May 2021; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2041210076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210076.